TNFRSF18 and neoplasm: Immunization with VEEV-TRP-2 and anti-GITR mAbs induced complete tumor regression in 90% of mice, whereas VEEV-TRP-2 and anti-CTLA-4 treatment resulted in tumor shrinkage in 50% of animals.